MSD-001
- Generic Name
- MSD-001
Pharma Companies Biohack Psychedelics for Safer Mental Health Therapies
• Pharmaceutical companies are developing next-generation psychedelic drugs like R-MDMA, aiming for safer psychotherapy treatments with fewer side effects.
• Mindstate is using AI to understand how psychedelics affect the brain and has FDA approval for human trials of MSD-001 (Moxy), targeting specific serotonin receptors.
• Companies are exploring synthetic versions of drugs like DMT to provide longer-lasting relief for depression, addressing the potential for unwanted "bad trips."
• While trials may take years, the research marks a step forward for psychedelic therapy, with potential applications in treating conditions like PTSD and depression.
Mindstate's AI-Designed Psychedelic MSD-001 Receives FDA and EMA Nod for Human Trials
• Mindstate Design Labs has received FDA and EMA approval to begin Phase 1 human trials for its AI-designed psychedelic compound, MSD-001.
• MSD-001 is designed to selectively target serotonin receptors, offering a more controlled and predictable psychoactive effect compared to traditional psychedelics.
• The Phase 1 trials will assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of MSD-001 in healthy participants.
• Mindstate's Osmanthus AI platform synthesizes extensive drug reports and biochemical data to design targeted states of consciousness, potentially expanding therapeutic applications.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath